Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miebo ECD Safety Study in Dry Eye Disease
NCT06565650Phase 4Active, not recruiting
- Sponsor
- Bausch + Lomb
- Start
- Jul 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of perfluorohexyloctane in dry eye disease (DED) (2 arms), sponsored by Bausch + Lomb. Primary endpoint: Mean change from baseline in Endothelial Cell Density at 12 months. Started Jul 2024; status: active, not recruiting.
02
Drugs
perfluorohexyloctane
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06565650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06565650.